Holy Spirit Hospital | |
503 North 21st Street, Camp Hill, Pennsylvania 17011 | |
(717) 763-2100 | |
Name | Holy Spirit Hospital |
---|---|
Type | Acute Care Hospital |
Location | 503 North 21st Street, Camp Hill, Pennsylvania |
Ownership | Voluntary non-profit - Private |
Emergency Services | Yes |
Medicare ID (CCN) | 390004 |
NPI Number | 1235579160 |
Organization Name | HOLY SPIRIT HOSPITAL |
Address | 503 N 21st St, Camp Hill, PA 17011 |
Hospital Type | General Acute Care Hospital |
Phone Number | 717-763-2100 |
News Archive
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, presented results from preclinical studies with TRX518, an early-stage agent Tolerx is developing as a treatment for cancer. TRX518 is a monoclonal antibody to glucocorticoid-induced tumor necrosis factor receptor (GITR) and is designed to enhance the immune system's ability to attack tumors by activating and rendering T effector cells resistant to T regulatory cell suppression.
The U.S. Food and Drug Administration today approved Tudorza Pressair (aclidinium bromide) for the long-term maintenance treatment of bronchospasm (narrowing of the airways in the lung) associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
The number of health savings accounts (HSAs) and health reimbursement arrangements (HRAs) increased to 5.7 million in 2010, according to a new report by the nonpartisan Employee Benefit Research Institute (EBRI). Assets in these account-based health plans increased to $7.7 billion in 2010.
Scientists at the Department of Infection and Immunity of the Luxembourg Institute of Health revealed a novel mechanism through which the immune system can control autoimmunity and cancer.
› Verified 3 days ago
NPI Number | 1639399751 |
Organization Name | HOLY SPIRIT HOSPITAL |
Doing Business As | HOLY SPIRIT HOSPITAL CARDIOLOGIST |
Address | 503 N 21st St, Camp Hill, PA 17011 |
Hospital Type | General Acute Care Hospital |
Phone Number | 717-763-2889 |
News Archive
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, presented results from preclinical studies with TRX518, an early-stage agent Tolerx is developing as a treatment for cancer. TRX518 is a monoclonal antibody to glucocorticoid-induced tumor necrosis factor receptor (GITR) and is designed to enhance the immune system's ability to attack tumors by activating and rendering T effector cells resistant to T regulatory cell suppression.
The U.S. Food and Drug Administration today approved Tudorza Pressair (aclidinium bromide) for the long-term maintenance treatment of bronchospasm (narrowing of the airways in the lung) associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
The number of health savings accounts (HSAs) and health reimbursement arrangements (HRAs) increased to 5.7 million in 2010, according to a new report by the nonpartisan Employee Benefit Research Institute (EBRI). Assets in these account-based health plans increased to $7.7 billion in 2010.
Scientists at the Department of Infection and Immunity of the Luxembourg Institute of Health revealed a novel mechanism through which the immune system can control autoimmunity and cancer.
› Verified 3 days ago
Able to receive lab results electronically | Yes |
Able to track patients' lab results, tests, and referrals electronically between visits | Yes |
News Archive
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, presented results from preclinical studies with TRX518, an early-stage agent Tolerx is developing as a treatment for cancer. TRX518 is a monoclonal antibody to glucocorticoid-induced tumor necrosis factor receptor (GITR) and is designed to enhance the immune system's ability to attack tumors by activating and rendering T effector cells resistant to T regulatory cell suppression.
The U.S. Food and Drug Administration today approved Tudorza Pressair (aclidinium bromide) for the long-term maintenance treatment of bronchospasm (narrowing of the airways in the lung) associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
The number of health savings accounts (HSAs) and health reimbursement arrangements (HRAs) increased to 5.7 million in 2010, according to a new report by the nonpartisan Employee Benefit Research Institute (EBRI). Assets in these account-based health plans increased to $7.7 billion in 2010.
Scientists at the Department of Infection and Immunity of the Luxembourg Institute of Health revealed a novel mechanism through which the immune system can control autoimmunity and cancer.
› Verified 3 days ago
Holy Spirit Hospital Acute Care Hospital Location: 503 North 21st Street, Camp Hill, Pennsylvania 17011 Phone: (717) 763-2100 |